1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EB6CE49E9EB2FA9885256FD400662B3A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharmaceutical-marketing-re-launch-excellence-white-paper?OpenDocument
18
19OpenDocument
203.90.12.112
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RC




Products & Services

Pharmaceutical Marketing: Re-Launch Excellence White Paper

ID: WP-26


Pages: 11


Published: Pre-2013


Delivery Format: Online


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download White Paper

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
This white paper leverages the perspectives and experiences of 19 brand leaders from a class of 14 top pharmaceutical companies to deliver a comprehensive best practice guide to re-launching underperforming pharmaceutical and bio-tech products. Insights have also been harvested from case studies of two successful drug re-launches - Zithromax and Wellbutrin.


Drawn from Best Practices, LLC's newest research initiative on product re-launch, this white paper contains complimentary best practices and insight on elements that must be considered when embarking upon a re-launch initiative:

  • Developing a Re-Launch Strategy: Detailed practices in this section describe how market leaders build the case for re-launching a product to company executives and devise the optimal strategy for maximum success.
  • Re-defining Product Character: Explores the strategies and tactics used by seasoned brand veterans to re-introduce a pharmaceutical product to physicians and thought leaders in a way that generates renewed excitement and support.
  • Winning the Hearts and Minds of the Sales Organization to the Re-Launch: Generating the enthusiasm and commitment of the sales team is focus of this chapter, which offers insights and lessons learned from brand leaders.
  • Marketing Investment Level: Survey data on optimal investment levels, marketing mix and rates of return models is presented and analyzed.

For an assessment of your re-launch effort or other marketing initiatives, contact Chris Bogan, President & CEO (919) 767-9228 or by email cbogan@best-in-class.com.

For more information on the complete study, visit: http://www.best-in-class.com/cr134.htm

Industries Profiled:
Pharmaceutical; Medical Device; Manufacturing; Biotech; Consumer Products; Diagnostic; Health Care


Companies Profiled:
AstraZeneca; Sanofi-aventis; Baxter International; Bayer; DSM Pharmaceutical; Eli Lilly and Company; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche; Schering-Plough; UCB Pharma